On Oct 25, major Wall Street analysts update their ratings for $Arcus Biosciences (RCUS.US)$, with price targets ranging from $20 to $46.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $35.
BofA Securities analyst Jason Zemansky maintains with a hold rating, and maintains the target price at $22.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $38 to $46.
Barclays analyst Peter Lawson maintains with a buy rating, and adjusts the target price from $25 to $29.
Truist Financial analyst Asthika Goonewardene maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcus Biosciences (RCUS.US)$'s main analysts recently are as follows:
The recent data on HIF2alpha confirmed that the overall response rate is comparable with that of competitors. There are several avenues to potentially improve this rate, considering that there are still five patients participating in the study.
The presentation of the first clinical activity data for casdatifan at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics has provided an evolving yet very favorable view of the clinical benefit/risk ratio. The inclusion of casdatifan in the model for post-immunotherapy treatment in metastatic clear cell renal cell carcinoma, with a projected success rate and anticipated launch year, reflects the analyst's positive outlook on its potential.
Here are the latest investment ratings and price targets for $Arcus Biosciences (RCUS.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月25日，多家華爾街大行更新了$Arcus Biosciences (RCUS.US)$的評級，目標價介於20美元至46美元。
摩根士丹利分析師Terence Flynn維持買入評級，維持目標價35美元。
美銀證券分析師Jason Zemansky維持持有評級，維持目標價22美元。
花旗分析師Yigal Nochomovitz維持買入評級，並將目標價從38美元上調至46美元。
巴克萊銀行分析師Peter Lawson維持買入評級，並將目標價從25美元上調至29美元。
儲億銀行分析師Asthika Goonewardene維持買入評級。
此外，綜合報道，$Arcus Biosciences (RCUS.US)$近期主要分析師觀點如下：
最新的HIF2alpha數據證實，總體應答率與競爭對手相當。有幾種可能提高這一比率的途徑，考慮到仍有五名參與研究的患者。
在2024年EORTC-NCI-AACR分子靶向和癌症治療會議上，首次展示了casdatifan的臨床活性數據，爲臨床利益/風險比提供了不斷髮展但非常有利的觀點。在模型中將casdatifan納入轉移性結清細胞腎癌免疫治療後治療的預期成功率和預期上市年份中，體現了分析師對其潛力的積極展望。
以下爲今日6位分析師對$Arcus Biosciences (RCUS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
